CASI
Income statement / Annual
Last year (2023), CASI Pharmaceuticals, Inc.'s total revenue was $33.88 M,
a decrease of 21.41% from the previous year.
In 2023, CASI Pharmaceuticals, Inc.'s net income was -$26.94 M.
See CASI Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$33.88 M |
$43.11 M |
$30.17 M |
$15.14 M |
$4.13 M |
$0.00 |
$0.00 |
$0.00 |
$47,712.00 |
$23,727.00 |
| Cost of Revenue |
$13.83 M
|
$15.83 M
|
$12.56 M
|
$9.51 M
|
$3.94 M
|
$1.67 M
|
$117,779.00
|
$66,451.00
|
$6,274.00
|
$7,467.00
|
| Gross Profit |
$20.05 M
|
$27.28 M
|
$17.61 M
|
$5.63 M
|
$196,000.00
|
-$1.67 M
|
-$117,779.00
|
-$66,451.00
|
$41,438.00
|
$16,260.00
|
| Gross Profit Ratio |
0.59
|
0.63
|
0.58
|
0.37
|
0.05
|
0
|
0
|
0
|
0.87
|
0.69
|
| Research and Development Expenses |
$9.86 M
|
$16.00 M
|
$14.42 M
|
$11.47 M
|
$9.75 M
|
$8.51 M
|
$7.60 M
|
$4.65 M
|
$4.08 M
|
$2.77 M
|
| General & Administrative Expenses |
$25.39 M
|
$23.45 M
|
$23.77 M
|
$19.66 M
|
$27.34 M
|
$18.00 M
|
$3.16 M
|
$4.78 M
|
$3.12 M
|
$3.76 M
|
| Selling & Marketing Expenses |
$16.45 M
|
$14.33 M
|
$14.71 M
|
$7.82 M
|
$3.10 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$41.84 M
|
$37.78 M
|
$38.47 M
|
$27.48 M
|
$30.44 M
|
$18.00 M
|
$3.16 M
|
$4.78 M
|
$3.12 M
|
$3.76 M
|
| Other Expenses |
-$6.57 M
|
$44,000.00
|
$558,000.00
|
$82,000.00
|
$5,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$45.13 M
|
$53.77 M
|
$52.89 M
|
$38.95 M
|
$40.19 M
|
$26.50 M
|
$10.75 M
|
$9.42 M
|
$7.19 M
|
$6.52 M
|
| Cost And Expenses |
$58.96 M
|
$69.60 M
|
$65.45 M
|
$48.45 M
|
$44.12 M
|
$26.50 M
|
$10.75 M
|
$9.42 M
|
$7.20 M
|
$6.53 M
|
| Interest Income |
$614,000.00
|
$127,000.00
|
$321,000.00
|
$866,000.00
|
$1.06 M
|
$48,196.00
|
$15,985.00
|
$7,718.00
|
$922.00
|
$1,483.00
|
| Interest Expense |
$0.00
|
$28.98 M
|
$0.00
|
$0.00
|
$0.00
|
$8,208.00
|
$14,976.00
|
$33,808.00
|
$82,455.00
|
$28,064.00
|
| Depreciation & Amortization |
$3.74 M
|
$2.42 M
|
$3.10 M
|
$3.23 M
|
$2.15 M
|
$1.67 M
|
$117,779.00
|
$66,451.00
|
$68,381.00
|
$48,179.00
|
| EBITDA |
-$21.54 M |
-$24.07 M |
-$32.75 M |
-$31.35 M |
-$37.43 M |
-$25.79 M |
-$10.64 M |
-$9.35 M |
-$7.06 M |
-$26.13 M |
| EBITDA Ratio |
-0.64
|
-0.18
|
-1.06
|
-1.07
|
-7.6
|
0
|
0
|
0
|
-148.46
|
-272.1
|
| Operating Income Ratio |
-0.74
|
-0.61
|
-1.17
|
-2.2
|
-9.68
|
0
|
0
|
0
|
149.91
|
1103.7
|
| Total Other Income/Expenses Net |
-$1.21 M
|
-$10.94 M
|
-$560,000.00
|
-$14.20 M
|
-$5.37 M
|
-$967,568.00
|
-$18,882.00
|
-$32,878.00
|
-$54,020.00
|
-$19.70 M
|
| Income Before Tax |
-$26.29 M
|
-$37.43 M
|
-$35.84 M
|
-$47.51 M
|
-$45.36 M
|
-$27.47 M
|
-$10.77 M
|
-$9.45 M
|
-$7.21 M
|
-$26.20 M
|
| Income Before Tax Ratio |
-0.78
|
-0.87
|
-1.19
|
-3.14
|
-10.98
|
0
|
0
|
0
|
-151.04
|
-1104.32
|
| Income Tax Expense |
-$81,000.00
|
$1.98 M
|
$1.93 M
|
$15.06 M
|
$6.05 M
|
-$958,914.00
|
$14,976.00
|
$33,808.00
|
$82,455.00
|
$28,064.00
|
| Net Income |
-$26.94 M
|
-$39.41 M
|
-$37.77 M
|
-$62.57 M
|
-$51.41 M
|
-$27.47 M
|
-$10.77 M
|
-$9.45 M
|
-$7.21 M
|
-$26.20 M
|
| Net Income Ratio |
-0.8
|
-0.91
|
-1.25
|
-4.13
|
-12.44
|
0
|
0
|
0
|
-151.04
|
-1104.32
|
| EPS |
-2.02 |
-2.89 |
-2.78 |
-5.66 |
-5.36 |
-3.24 |
-1.75 |
-1.69 |
-2.22 |
-9.16 |
| EPS Diluted |
-2.02 |
-2.89 |
-2.78 |
-5.66 |
-5.36 |
-3.24 |
-1.75 |
-1.69 |
-2.22 |
-9.16 |
| Weighted Average Shares Out |
$13.36 M
|
$13.65 M
|
$13.61 M
|
$11.05 M
|
$9.59 M
|
$8.48 M
|
$6.15 M
|
$5.59 M
|
$3.24 M
|
$2.86 M
|
| Weighted Average Shares Out Diluted |
$13.36 M
|
$13.65 M
|
$13.61 M
|
$11.05 M
|
$9.59 M
|
$8.48 M
|
$6.15 M
|
$5.59 M
|
$3.24 M
|
$2.86 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
